GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (XTER:BIO) » Definitions » Cyclically Adjusted Revenue per Share

Biotest AG (XTER:BIO) Cyclically Adjusted Revenue per Share : €14.80 (As of Mar. 2024)


View and export this data going back to 1987. Start your Free Trial

What is Biotest AG Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biotest AG's adjusted revenue per share for the three months ended in Mar. 2024 was €5.398. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €14.80 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biotest AG's average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biotest AG was 5.40% per year. The lowest was -0.50% per year. And the median was 2.45% per year.

As of today (2024-06-23), Biotest AG's current stock price is €41.00. Biotest AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €14.80. Biotest AG's Cyclically Adjusted PS Ratio of today is 2.77.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biotest AG was 3.42. The lowest was 1.44. And the median was 2.42.


Biotest AG Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biotest AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Cyclically Adjusted Revenue per Share Chart

Biotest AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.46 12.38 12.99 13.86 14.50

Biotest AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.10 14.13 14.50 14.50 14.80

Competitive Comparison of Biotest AG's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Biotest AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biotest AG's Cyclically Adjusted PS Ratio falls into.



Biotest AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biotest AG's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.398/125.0381*125.0381
=5.398

Current CPI (Mar. 2024) = 125.0381.

Biotest AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 3.601 99.543 4.523
201409 3.623 99.823 4.538
201412 4.349 99.543 5.463
201503 3.732 99.717 4.680
201506 3.630 100.417 4.520
201509 3.293 100.417 4.100
201512 2.949 99.717 3.698
201603 3.711 100.017 4.639
201606 3.417 100.717 4.242
201609 3.333 101.017 4.126
201612 -0.147 101.217 -0.182
201703 1.669 101.417 2.058
201706 2.373 102.117 2.906
201709 2.536 102.717 3.087
201712 2.777 102.617 3.384
201803 2.184 102.917 2.653
201806 2.848 104.017 3.424
201809 2.266 104.718 2.706
201812 2.798 104.217 3.357
201903 2.583 104.217 3.099
201906 2.573 105.718 3.043
201909 2.648 106.018 3.123
201912 2.507 105.818 2.962
202003 2.533 105.718 2.996
202006 3.782 106.618 4.435
202009 2.758 105.818 3.259
202012 3.520 105.518 4.171
202103 3.149 107.518 3.662
202106 3.697 108.486 4.261
202109 2.924 109.435 3.341
202112 3.435 110.384 3.891
202203 3.075 113.968 3.374
202206 3.567 115.760 3.853
202209 2.787 118.818 2.933
202212 3.848 119.345 4.032
202303 3.045 122.402 3.111
202306 3.914 123.140 3.974
202309 6.389 124.195 6.432
202312 4.657 123.773 4.705
202403 5.398 125.038 5.398

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biotest AG  (XTER:BIO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biotest AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=41.00/14.8
=2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biotest AG was 3.42. The lowest was 1.44. And the median was 2.42.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biotest AG Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biotest AG's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (XTER:BIO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (XTER:BIO) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.